Abstract
Background: Some patients present with features of both primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) on the one hand and autoimmune hepatitis (AIH) on the other hand, either simultaneously or consecutively. The term ‘overlap syndrome (OS)' is used to describe these settings, but lack of universal agreement on what precisely constitutes an OS has generated considerable confusion. The low prevalence of OS (roughly 10% of PBC or PSC) has made it impracticable to perform randomized controlled trials. It remains unclear whether this syndrome forms a distinct entity or is a variant of PBC, PSC or AIH. Key Messages: Moderate to severe interface hepatitis is a fundamental component and histology is vital in evaluating patients with overlap presentation. Use of the International Autoimmune Hepatitis Group criteria for the diagnosis of OS is not recommended. For PBC-AIH OS, EASL has provided diagnostic criteria and, in most cases, it is possible to define one primary disorder (‘dominant' disease), usually PBC. Patients with OS seem to have a more severe disease compared to conventional PBC. PSC-AIH OS is assumed to exist in a considerable part of mainly young patients with autoimmune liver disease and long-term progression towards cirrhosis seems to occur in the majority of cases. In children, the hepatitic feature can be very dominant, and up to 50% of pediatric AIH have cholangiographic abnormalities suggestive of PSC (autoimmune sclerosing cholangitis). Treatment of OS is empiric and includes ursodeoxycholic acid for the cholestatic component (depending on local policy for PSC) and immunosuppressive agents for the hepatitic component, either simultaneously or sequentially. The dominant clinical feature should be treated first and therapy adjusted according to the response. Conclusions: OS is not uncommon but should not be over-diagnosed in order not to expose unnecessarily PBC or PSC patients to the risk of steroid side effects. Therapy has to be individualized and not be static.
References
1.
Bunchorntavakul C, Reddy KR: Diagnosis and management of overlap syndromes. Clin Liver Dis 2015;19:81-97.
2.
Burak KW, Urbanski SJ, Swain MG: A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci 2001;46:2043-2047.
3.
Floreani A, Motta R, Cazzagon N, Franceschet I, Roncalli M, Del Ross T, Rosina F, et al: The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Dig Liver Dis 2015;47:432-435.
4.
Trivedi PJ, Hirschfield GM: Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther 2012;36:517-533.
5.
Heathcote EJ: Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97:1090-1092.
6.
Lohse AW, zum Büschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP: Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-1084.
7.
van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MJ: A 38-year-old African-American woman with an unusually rapid progression of ‘primary biliary cirrhosis': a missed opportunity! Semin Liver Dis 2002;22:395-406.
8.
Woodward J, Neuberger J: Autoimmune overlap syndromes. Hepatology 2001;33:994-1002.
9.
O'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ: Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008;48:550-556.
10.
Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, et al: Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25:1090-1095.
11.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM: Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
12.
Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E: Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-385.
13.
Czaja AJ, Carpenter HA: Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-665.
14.
Kobayashi M, Kakuda Y, Harada K, Sato Y, Sasaki M, Ikeda H, Terada M, et al: Clinicopathological study of primary biliary cirrhosis with interface hepatitis compared to autoimmune hepatitis. World J Gastroenterol 2014;20:3597-3608.
15.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, et al: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
16.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, et al: Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-176.
17.
Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R: Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301.
18.
Heurgué A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, Picot R, et al: Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol 2007;31:17-25.
19.
Kuiper EM, Zondervan PE, van Buuren HR: Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010;8:530-534.
20.
European Association for the Study of the Liver: EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
21.
Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, Menichella R, et al: The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009;104:1420-1425.
22.
Poupon R, Chazouilleres O, Corpechot C, Chrétien Y: Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44:85-90.
23.
Horsmans Y, Piret A, Brenard R, Rahier J, Geubel AP: Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: a case report. J Hepatol 1994;21:194-198.
24.
Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R: Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44:400-406.
25.
Neuhauser M, Bjornsson E, Treeprasertsuk S, Enders F, Silveira M, Talwalkar J, Lindor K: Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010;105:345-353.
26.
Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ: Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-413.
27.
Rust C, Beuers U: Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008;14:3368-3373.
28.
Ozaslan E, Efe C, Heurgué-Berlot A, Kav T, Masi C, Purnak T, Muratori L, et al: Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014;12:863-869.
29.
Gossard AA, Lindor KD: Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int 2007;27:1086-1090.
30.
Wilschanski M, Chait P, Wade JA, Davis L, Corey M, St Louis P, Griffiths AM, et al: Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-1422.
31.
Gohlke F, Lohse AW, Dienes HP, Löhr H, Märker-Hermann E, Gerken G, Meyer zum Büschenfelde KH: Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996;24:699-705.
32.
van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP: High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33:543-548.
33.
Kaya M, Angulo P, Lindor KD: Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33:537-542.
34.
Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, Ziol M, et al: Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009;50:528-537.
35.
Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ: Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47:949-957.
36.
Perdigoto R, Carpenter HA, Czaja AJ: Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-331.
37.
Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G: Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.
38.
Olsson R, Glaumann H, Almer S, Broomé U, Lebrun B, Bergquist A, Björnsson E, et al: High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med 2009;20:190-196.
39.
Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T, González-Peralta RP, et al: Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009;49:158-164.
40.
Abdo AA, Bain VG, Kichian K, Lee SS: Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36:1393-1399.
41.
Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ: Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
42.
Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA: Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28:209-220.
43.
Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V: Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516-1522.
44.
Lüth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, Galle PR, et al: Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009;43:75-80.
45.
Bhanji RA, Mason AL, Girgis S, Montano-Loza AJ: Liver transplantation for overlap syndromes of autoimmune liver diseases. Liver Int 2013;33:210-219.
46.
Czaja AJ: The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013;58:326-343.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
